Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

D. K. Hiwase; D. L. White; V. A. Saunders; S. Kumar; J. V. Melo; T. P. Hughes

doi:10.1038/leu.2009.45

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL⁺ cells

D. K. Hiwase, D. L. White, V. A. Saunders, S. Kumar, J. V. Melo, T. P. Hughes

Blood Cancer Program

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Original language	English
Pages (from-to)	1205-1206
Number of pages	2
Journal	Leukemia
Volume	23
Issue number	6
DOIs	https://doi.org/10.1038/leu.2009.45
Publication status	Published or Issued - 2009

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2009.45

Cite this

@article{fcdc38c7cc23480ba3d72ec9152dc22d,

title = "Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells",

author = "Hiwase, \{D. K.\} and White, \{D. L.\} and Saunders, \{V. A.\} and S. Kumar and Melo, \{J. V.\} and Hughes, \{T. P.\}",

year = "2009",

doi = "10.1038/leu.2009.45",

language = "English",

volume = "23",

pages = "1205--1206",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

AU - Hiwase, D. K.

AU - White, D. L.

AU - Saunders, V. A.

AU - Kumar, S.

AU - Melo, J. V.

AU - Hughes, T. P.

PY - 2009

Y1 - 2009

UR - https://www.scopus.com/pages/publications/67349128598

U2 - 10.1038/leu.2009.45

DO - 10.1038/leu.2009.45

M3 - Article

C2 - 19262594

AN - SCOPUS:67349128598

SN - 0887-6924

VL - 23

SP - 1205

EP - 1206

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL⁺ cells